Muscle-invasive bladder cancer (MIBC) remains one of the most aggressive urologic cancers, with poor long-term outcomes driven by limited systemic therapy options and frequent micrometastatic disease at diagnosis. Immune checkpoint inhibitors (ICIs) are transforming the treatment landscape and improving pathologic response rates and survival, but the pace of innovation has created significant challenges for clinicians to integrate into practice. At the same time, treatment-related adverse events can profoundly impact quality of life, making informed shared decision-making essential. In this CE Concepts AI-enabled clinical simulation, learners are immersed in real-world MIBC scenarios where they must evaluate evidence, navigate cisplatin eligibility and treatment selection, engage in shared decision-making with individuals facing curative-intent choice, and manage treatment/immune-related adverse events thereby building the clinical fluency required to deliver evidence-based, patient-centered care.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
100% of listed courses are free
18 of 18 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- No reviews yet. Be the first to share yours.



